✦ LIBER ✦

Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer

✍ Scribed by David A. August; Paul H. Sugarbaker; Philip D. Schneider

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 607 KB
Volume: 55
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19850401)55:7<1490::aid-cncr2820550712>3.0.co;2-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liver metastases found by follow-up of p

Liver metastases found by follow-up of patients operated on for colorectal cancer

✍ O. Almersjö; S. Bengmark; Lo. Hafström 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

The biology of colorectal cancer. Implic

The biology of colorectal cancer. Implications for pretreatment and follow-up management

✍ C. Richard Boland 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

Prognostic index for the development of

Prognostic index for the development of liver metastases in patients with colorectal cancer

✍ Professor I. Taylor; M. A. Mullee; M. J. Campbell 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB 👁 2 views

## Abstract The incidence of synchronous and metachronous liver metastases in patients with colorectal cancer is extremely high. Approximately 25 per cent of patients will have overt liver metastases at the time of presentation, and in the remainder up to 40 per cent will eventually develop liver m

Cost-effectiveness of systemic and regio

Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases

✍ Isabelle Durand-Zaleski; Sally Earlam; Carol Fordy; Michael Davies; Timothy G. A 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 3 views

## Background: Management of unresectable colorectal liver metastases (clm) can be by regional (hepatic arterial infusion [hai]) or systemic chemotherapy, or by symptom control alone. in this study the costs of each type of management were related to clinical outcome in 134 patients with clm. ## M

Validation of the European Organization

Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases

✍ J. M. Blazeby; P. Fayers; T. Conroy; O. Sezer; J. Ramage; M. Rees 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 3 views

## Abstract ## Background There is a lack of valid patient-reported outcome (PRO) measures for hepatectomy or palliative treatment of colorectal hepatic metastases. This study examined the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life qu

The impact of detection and treatment on

The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer

✍ David H. Howard; Florence K. Tangka; Laura C. Seeff; Lisa C. Richardson; Donatus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

## Abstract Understanding the costs associated with early detection of disease is important for determining the fiscal implications of government‐funded screening programs. We estimate the lifetime medical costs for patients with screen‐detected versus undetected polyps and early‐stage colorectal c